Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD76m

    Last close

    USD0.81

    ▲ 0.14 (20.90%)

    Canyon Resources

    MCap

    AUD262m

    Last close

    AUD0.19

    ▲ 0.02 (12.12%)

    Immix Biopharma

    MCap

    USD51m

    Last close

    USD1.82

    ▲ 0.12 (7.06%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Biodexa Pharmaceuticals (NASDAQ: BDRX)

Last close As at 21/11/2024

0.99

▲ −0.03 (−2.94%)

Market capitalisation

5m

Edison Investment Research is terminating coverage on Biodexa Pharmaceuticals (BDRX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Latest Insights

View More

Healthcare | Update

Biodexa Pharmaceuticals — In a period of transition

Healthcare | Update

Biodexa Pharmaceuticals — Foray into T1D expands business scope

Healthcare | Flash note

Biodexa Pharmaceuticals — Tolimidone licensing expands clinical pipeline

Healthcare | Flash note

Biodexa Pharmaceuticals — Acquisition of Varian Bio to bolster pipeline
Midatech Pharma_resized
Visit Website

Sector

Healthcare

Balance Sheet

Forecast net debt (£m)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (16.1) (22.7) (85.2)
Relative (19.6) (26.6) (88.2)
52 week high/low US$8.0/US$0.7

Financials

Edison Investment Research is terminating coverage on Oxford Cannabinoid Technologies (OCTP), Britvic (BVIC), Ultimovacs (ULTI), DFR Gold (DFR), The Merchants Trust (MRCH), PB Holding (PBH) and Biodexa Pharmaceuticals (BDRX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Y/E Dec Revenue (£m) EBITDA (£m) PBT (£m) EPS (p) P/E (x) P/CF (x)
2022A 0.7 (8.6) (8.5) (6.30) N/A N/A
2023A 0.4 (7.7) (7.5) (5.30) N/A N/A
2024E N/A N/A N/A N/A N/A N/A
2025E N/A N/A N/A N/A N/A N/A

Flash note

Healthcare

Midatech Pharma — MTX110 receives ODD from the EMA for gliomas

Flash note

Healthcare

Midatech Pharma — Interim DIPG data to be presented at ISPNO

Flash note

Healthcare

Midatech Pharma — MTX110’s path to market fast-tracked in rGBM

Update

Healthcare

Midatech Pharma — Pipeline delivery key to future outlook

edison tv

Healthcare

Midatech Pharma: Edison Open House Healthcare 2022

Flash note

Healthcare

Midatech Pharma — Q-Sphera partnership with Janssen expanded

Initiation

Healthcare

Midatech Pharma — Pivoting its commercial strategy

edison tv

Healthcare

Midatech Pharma – Edison Open House interview